A Phase I/II, Open-label, Multi-center Study of the Safety and Efficacy of BLZ945 as Single Agent and in Combination With PDR001 in Adults Patients With Advanced Solid Tumors

Trial Profile

A Phase I/II, Open-label, Multi-center Study of the Safety and Efficacy of BLZ945 as Single Agent and in Combination With PDR001 in Adults Patients With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 26 Feb 2018

At a glance

  • Drugs BLZ 945 (Primary) ; Spartalizumab (Primary)
  • Indications Breast cancer; Glioblastoma; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 22 Feb 2018 Planned End Date changed from 18 Oct 2019 to 25 Mar 2019.
    • 22 Feb 2018 Planned primary completion date changed from 18 Oct 2019 to 25 Mar 2019.
    • 27 Oct 2016 Planned End Date changed from 1 Jun 2019 to 1 Oct 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top